C-Reactive Protein and Cardiovascular Risk in the General Population: A European Heart Journal Study by Berkan Kurt et al.
Berkan Kurt, Resident Physician in Cardiology and Internal Medicine at Uniklinik RWTH Aachen, posted on LinkedIn:
“Deeply grateful to share that our article “C-reactive protein and cardiovascular risk in the general population” has now been published in the European Heart Journal.
In 448 653 adults without known ASCVD, a single hsCRP measurement showed strong stability over time, displayed long-term inflammatory risk, and independently predicted MACE, CV death and all-cause mortality across clinically relevant subgroups, including SMuRF-less but inflamed individuals. hsCRP ranked among the strongest predictors of CV outcomes and added incremental value to SCORE2-based risk prediction. 
Our findings underscore residual inflammatory risk as an additional, relevant dimension in primary prevention. Routine hsCRP assessment should be considered for inclusion in future guidelines to refine CV risk assessment and to improve prevention strategies in patients without a history of ASCVD.
Sincerely thankful to my mentor Florian Kahles for his continuous support and guidance, my colleague Martin Reugels for the outstanding work together on this project, and to all co-authors and international colleagues for their generous collaboration and the privilege of working together with leading experts in the field.
Open access article”
Title: C-reactive protein and cardiovascular risk in the general population
Authors: Berkan Kurt, Martin Reugels, Kai M Schneider, Jens Spiesshoefer, Andrea Milzi, Alexander Gombert, Christopher B Fordyce, Florian A Wenzl, Neha J Pagidipati, Viviane Rocha, Marat Fudim, Abhinav Sharma, Michael Lehrke, Hiroaki Shimokawa, Giovanna Liuzzo, Lale Tokgozoglu, Filippo Crea, Thomas F Lüscher, Peter Libby, Paul M Ridker, Nikolaus Marx, Carolin V Schneider, Florian Kahles
Get the latest from Hemostasis Today.
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial